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We report the accidental needlestick inoculation of a
laboratory worker with vaccinia virus. Although the patient
had previously been vaccinated against smallpox, severe
lesions appeared on the fingers. Western blot and poly-
merase chain reaction–restriction fragment length polymor-
phism were used to analyze the virus recovered from the
lesions. The vaccinia virus–specific immunoglobulin G lev-
els were measured by enzyme-linked immunosorbent
assay. Our study supports the need for vaccination for lab-
oratory workers that routinely handle orthopoxvirus.
T
he smallpox vaccine, formulated with vaccinia virus,
is a highly effective immunizing agent. In 1980, the
World Health Organization certified that the world was
free of naturally occurring smallpox, and smallpox immu-
nization programs were subsequently discontinued (1).
Vaccination is still recommended for particular groups,
namely, healthcare workers who handle materials poten-
tially infected with vaccinia virus or other orthopoxviruses
that infect humans (2). 
The use of vaccinia virus in laboratories is likely to
increase as a consequence of international concerns about
the potential use of variola (smallpox) virus as a bioterror-
ism weapon. The vaccine is considered safe but can pro-
duce mild to moderate disease in vaccinees and can be dis-
seminated to their close contacts (1,3,4). Accidental infec-
tions have also been reported. In 1991, an accidental infec-
tion with recombinant vaccinia virus was described after a
needlestick injury on the left thumb of a laboratory work-
er (5). A case of vaccinia keratouveitis has been reported
after accidental ocular autoinoculation from a recent vac-
cination site (6). We now report the accidental infection of
a laboratory worker who manipulated vaccinia
virus–infected cells. 
Case Report
A 26-year-old healthy laboratory worker, previously
vaccinated against smallpox in childhood, sought treat-
ment in March 2002 with a history of pain followed by the
appearance of erythema and a pustule on the left thumb
(Figure 1A). These symptoms appeared 3 days after she
experienced an accidental needlestick while working with
material from a vaccinia virus (strain WR)–infected cell
culture during a virus purification procedure. Local symp-
toms worsened, and on the days 5 and 6, respectively, she
noticed new pustules on the fourth and fifth fingers of the
same hand (Figure 1E). Axillary lymphadenopathy was
noticed on the day 6 after the accident. On day 8, necrotic
areas around the lesions and a large erythemathous lesion
appeared on the left forearm. On day 9 after inoculation,
the local lesions worsened and amoxicillin/clavunate
(1,750/250 mg per day) was administered because of a
clinical suspicion of secondary bacterial infection (Figure
1B, F). The hand lesions were surgically excised to remove
the necrotic tissue, and pustular fluid was collected for
analysis (Figure 1C, G). After the surgical procedure, the
patient improved slowly until she made a full recovery
(Figure 1D, H), and the lesions healed in approximately 3
weeks.
Results
Pustular fluid from the lesions was collected and tested
for the presence of bacteria and virus. The Gram stain and
cultures were negative for bacteria. When a diluted sample
of the pustular fluid was added to BSC-40 (monkey kid-
ney) cell culture, a poxviruslike cytopathic effect was evi-
dent after 48 h of infection (data not shown). Vaccinia
virus proteins were detected in infected cells by 12% sodi-
um dodecylsulfate–polyacrylamide gel electrophoresis
(SDS-PAGE), followed by Western Blot analysis with rab-
bit antiserum raised against total vaccinia virus proteins as
described before (7). The protein profile was indistinguish-
able from that of the WR strain of vaccinia virus currently
used in the laboratory (Figure 2A). The presence of vac-
cinia virus genome in the pustular fluid could be demon-
strated by polymerase chain reaction (PCR), followed by
restriction fragment length polymorphism (RFLP) of the
phenol-chloroform–extracted DNA from BSC-40 cells
infected with the clinical sample for 24 h at 37°C (8). Total
DNA isolated from cells infected with the vaccinia
virus–WR was used as reference. Two regions of the vac-
cinia virus genome were analyzed by using the following
PCR primers: A24Rfwd 5′ATGAAAAAAAACACT-
GATTC and A24Rrev 5′TTACACCAGAAAAGACG-
GCT; B9Rfwd 5′GACTAAATATTCATAA and B14Rrev
5′TACTAAAGTTCCGTCATC. The A24R gene was used
as marker for the nonvariable region of the virus genome,
and the PCR amplicons were digested with the endonucle-
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USA), as recommended by the manufacturer. The variable
region of vaccinia virus genome was investigated by
amplifying the DNAsegment from the B9R to B14R genes
and digestion of the amplicons with EcoR V and AluI (Life
Technologies, Rockville, MD, USA), as recommended.
The digestion products were analyzed by using 1.2%
agarose gels. The restriction patterns obtained for both
regions in the test sample were identical to the profiles
observed with the genome of vaccinia virus–WR (Figure
2B). 
Serum collected from the patient day 20 after the initial
inoculation was tested for vaccinia virus–specific
immunoglobulin (Ig) G response by enzyme-linked
immunosorbent assay (ELISA) as described (9,10).
Purified vaccinia virus (1 µg/mL in 0.05 M carbonate
buffer, pH 9.6) was used as the antigen, and the serum
samples were diluted 1/100. Bound antibodies were detect-
ed with peroxidase-labeled, anti-human IgG (Biolab
Diagnóstica, São Paulo, Brazil) dulated 1/8,000 as
described (9,10). The optical density (OD) values were
obtained with a microtiter plate spectrophotometer at 450
nm (BioRad, Model 3550 UV, Bio-Rad Laboratories,
Hercules, CA, USA). The test serum specimen was com-
pared to a panel of serum specimens from 22 unvaccinat-
ed persons and 11 persons who had been vaccinated some
time previously, including a sample from the laboratory
worker taken 6 years before the accident. When we com-
pared the serum specimens collected before and after the
accident, we observed an increase by a factor of 3.5 in the
IgG-antibody response to vaccinia virus (Figure 2C).
Furthermore, the vaccina virus–specific IgG levels in the
test serum were 1.6 to 2.8 times higher than the levels in
the panel of positive control samples and >5 times higher
than levels in naive persons. Together, these results con-
firm that after the recent accident, a productive infection
was found in the lesion and an immune response to vacci-
na virus was elicited.
Conclusions
Accidental infection with live pathogens by healthcare
and laboratory workers has been frequently reported
(11,12). The risk of infection cannot be avoided, although
it can be prevented or minimized by safety measures. In
some cases, vaccination of the workers is the best way to
prevent the disease; however, vaccines are not always
available. 
We report the response of a laboratory worker to an
accidental needlestick inoculation with vaccinia virus in
2002. After the accident, typical symptoms of vaccinia
infection developed in the worker, followed by full recov-
ery 4 weeks later. Vaccinia virus could be reisolated from
the pustular fluid, and no major variation from the original
seed virus was detected. Although the patient had been
vaccinated against smallpox >20 years ago, a serum sam-
ple isolated 6 years before the accident showed a level of
vaccina virus–specific IgG antibodies approximately 2
times higher than the level in naive persons. This level of
humoral immunity was not able to prevent the progression
of the infection as would be expected if she had been vac-
cinated recently. This result indicates that despite the high
IgG levels induced after vaccina virus inoculation, persons
vaccinated for >20 years are no longer fully protected
against vaccina virus infection and could be vulnerable to
variola virus or other orthopoxviruses that infect humans. 
Nevertheless, we should consider some aspects of this
accident that are not common in other situations (e.g.,
revaccination). The amount of virus in the needle before
the accident was approximately 1,000 times higher than
the amount in the vaccine preparations used for smallpox
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Figure 1. Progression of the local reaction on the left hand after accidental needlestick inoculation with vaccinia virus: thumb (A, day 4;
B, day 11; C, day 12; D, day 20; fourth and fifth fingers (E, day 7, F, day 11; G, day 12; H, day 20). Lesions were surgically excised to
remove necrotic tissue on day 11. Arrows indicate the lesion areas.vaccination (1). Even in a recently vaccinated person, a
response to an infection of such high magnitude will most
likely result in a local lesion. However, the question of
whether a major reaction with severe symptoms would
emerge in this hypothetical situation remains. Usually, a
severe reaction has occurred only when a long period has
elapsed after vaccination (1). Therefore, after a properly
conducted risk assessment, laboratory workers vaccination
should be considered as an occupational protection
measure against accidental exposure to orthopoxviruses.
The results of this study support the current Advisory
Committee on Immunization Practices guidelines that
recommend a 1-year vaccination regimen for workers who
handle low-virulence poxvirus and a 3-year regimen for
workers that handle high-virulence strains.
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Figure 2. Characterization of the pustular fluid and serologic
responses to vaccinia virus antigens. A) Western blot analysis of
BSC-40 cells mock-infected (1); infected with vaccinia virus WR
(2); or infected with 20 mL of the pustular fluid (3). Molecular
weights are expressed in kDa. B) Polymerase chain
reaction–restriction fragment length polymorphism analysis of vac-
cinia virus genome regions. Amplicons corresponding to the A24R
gene or the segment between the B9R and B14R genes were
digested or not (ND) with the restriction enzymes indicated on the
top of the figure. (1) vaccinia virus–WR; (2) clinical sample. C)
Detection of vaccinia virus–specific immunoglobulin G antibodies
in serum samples from nonvaccinated (NV) and vaccinated per-
sons (V) and the test subject (TS) was performed by enzume-
linked immunosorbent assay, and the results are expressed as
optical density 450-nm readings. The horizontal bar indicates the
cut-off for the test.